cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (ACT-ONE)

cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (ACT-ONE)

Collection of venous blood samples in 50 persons with type 1 diabetes to evaluate the behavior of different biomarkers (glucose, lactate, beta-hydroxybutyrate), and hormones (cortisol, growth hormone) during and after one morning CardioPulmonary Exercise Test and 2 aerobic (90 minutes at 40-45% of VO2 max) exercise tests under different circumstances (see Protocol).

Study Overview

• Status: Not yet recruiting
• Conditions: Diabetes Mellitus, Type 1
• Intervention / Treatment: Other: CPET: CardioPulmonary Exercise Test for CSII users; Other: AEX1: Aerobic Exercise Test 1 for CSII users; Other: AEX2: Aerobic Exercise Test 2 for CSII users; Other: CPET: CardioPulmonary Exercise Test for MDI users; Other: AEX1: Aerobic Exercise Test 1 for MDI users; Other: AEX2: Aerobic Exercise Test 2 for MDI users

Detailed Description

This study is an extension of the Action-1 pilot study. This study is an extension of the Action-1 pilot study. The aim is to collect samples of multiple biomarkers (circulating glucose, ketones and lactate levels) and hormones (cortisol and growth hormone) during and following an anaerobic and two aerobic exercise in patients with T1D, under more and well-defined circumstances (bolus insulin reduction in combination with major vs. minor basal insulin reduction) to aim for safer glucose levels during and after exercise (~90-180 mg/dL or ~5-10 mmol/L) and avoid extreme glucose excursions to hypo (< 70 mg/dL or <3.9 mmol/L) or hyperglycemia (>180 mg/dL or >10 mmol/L). Based on these data, we aim to formulate exercise guidelines to better help prevent hypoglycemia during and after exercise. Overall, our goal is to help maintain target glycemic values during and after exercise, as evidenced by >70% time in range (70-180mg/dL) while using Continuous Glucose Monitoring (CGM).

Primary endpoint:

• CGM outcomes during and after morning exercise, determined as:

• Time in range (TIR) 70-180mg/dL
• Time below range (TBR) Level 2, <54 mg/dL
• Time below range (TBR) Level 1 and 2, <70 mg/dL
• Time above range (TAR) Level 1 and 2, >180 mg/dL
• Time above range (TAR) Level 2, >250 mg/dL

Secondary endpoints:

• Evaluate values and trends of glucose, lactate and beta-hydroxybutyrate before, during and after morning exercise in venous blood.
• Evaluate trends of cortisol and growth hormone before, during and after exercise in relationship to possible hypoglycemic (<70mg/dL glucose) and hyperglycemic events (>180mg/dL).

One CardioPulmonary Exercise Test (CPET, symptom limited maximal exercise test) and two Aerobic Exercise Tests at 40-45% VO2max (AEX), with venous blood samples (catheter), heart rate monitoring during the exercise and follow-up to 6h after the exercise.

(The individual VO2max, using a CardioPulmonary Exercise Test, can be determined during the first "Symptom Limited Maximal" Exercise Test. This to assess the VT1 (V-slope relation VCO2 and VO2; Eq02), VT2 (Relation VE and VCO2; EqCO2) and VO2 peak.)

Before exercise Test 1, the CPET, the study participants will receive 7 questions on the physical activity over the last 7 days (IPAQ questionnaire).

The 3 Exercise Tests will be carried out with 2-4 weeks intervals:

• The day before an exercise test and right before, no exercise (only ADL) is allowed (patients should not come to the study center by bike)
• The night before the exercise test, no hypoglycemia must occur, as defined by 15 consecutive minutes, or more, of an interstitial glucose <70 mg/dL
• Target glucose level in the morning: 90-180 mg/dL
• The morning of the exercise test: patients will receive a standardized breakfast (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight)
• Breakfast at 30 minutes before the exercise with a bolus at the start of the breakfast (100% bolus for CPET, 50% bolus for AEX)
• Pump settings: basal insulin reduction through temporary target of 150 mg/dL during AEX1 and AEX2 will be adjusted 60-120 minutes prior to the start of the exercise and will last until 60 minutes after the exercise (210-270 min in total)
• Lunch (slices of bread with protein spread (containing ±5-25g of protein in total) of in total 0.5g carbohydrates per kg body weight) will be served after 2h of follow-up with a 75% insulin bolus and a correction bolus, if necessary, of 50% of the patient's usual insulin correction dose for the level of hyperglycemia observed.
• Hyperglycemia (>250mg/dL) before, during and after exercise will be corrected according to the patient's treatment schedule at 50% of the patient's usual correction factor.
• Glucose levels below the target glucose of 90 mg/dL during exercise will be corrected with fast-acting carbohydrates: 15g of oral glucose (sports beverage Aquarius Red Peach (7.4g CHO/100ml)), as repeated every 15 minutes, if necessary, until interstitial and/or whole blood glucose is > 70 mg/dL.

CPET:

• Baseline
• VO2peak measurement
• Breakfast
• 100% bolus insulin
• CSII: 100% basal
• MDI: 100% basal

AEX1:

• 90min
• 40-45% VO2peak
• Breakfast
• 50% bolus insulin
• CSII: -2h target 150 mg/dL
• MDI: 50% basal

AEX2:

• 90min
• 40-45% VO2peak
• Breakfast
• 50% bolus insulin
• CSII: -1h target 150 mg/dL
• MDI: 80% basal

CPET = CardioPulmonary Exercise Test; AEX = Aerobic Exercise Test; CSII = Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps); MDI = Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Christophe De Block, MD, PhD; Phone Number: +3238214364; Email: christophe.deblock@uza.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Duration of type 1 diabetes mellitus >5y
• Subjects willing to sign an informed consent form (ICF)
• Age 18-60y
• Using a continuous glucose monitoring system (preferably Guardian or Dexcom for CSII / Freestyle Libre for MDI)
• For CSII: only hybrid closed loop pumps (HCL)
• For MDI: only Tresiba (degludec) & Toujeo (glargine)
• HbA1c 6-8.0% (blood result up to 3 months old)
• BMI 20-27.5 kg/m2
• The participant should be in the categories 'moderately' to 'highly physically active' according to the IPAQ score
• The Physical Activity Coefficient has not changed (from category1) in the 2 months prior to the first Exercise Test

Exclusion Criteria:

• Being pregnant or having an active pregnancy wish
• Subject not on MDI or CSII
• Musculoskeletal disorder that affects cycling or is a contra-indication for vigorous physical activity
• Cardiorespiratory disease or ECG abnormality that is a contra-indication for vigorous physical activity
• Having an acute illness (e.g. influenza) that interferes with glucose metabolism
• Having a metabolic disorder (different from diabetes) known to have significant interference with glucose metabolism
• Current treatment with drugs known to have significant interference with glucose metabolism, such as systemic corticoids as judged by the investigator
• Presence of concomitant pathology such as heart failure, liver failure, kidney failure (defined as eGFR <45mL/min, blood result up to 12 months old)
• (Severe) food allergies as judged by the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: CSII users; Patients using Continuous Subcutaneous Insulin Infusion (only hybrid closed loop pumps)	Other: CPET: CardioPulmonary Exercise Test for CSII users; Baseline; VO2peak measurement; Breakfast; 100% bolus insulin; CSII users: 100% basal; Other: AEX1: Aerobic Exercise Test 1 for CSII users; 90min; 40-45% VO2peak; Breakfast; 50% bolus insulin; CSII users: -2h target 150 mg/dL; Other: AEX2: Aerobic Exercise Test 2 for CSII users; 90min; 40-45% VO2peak; Breakfast; 50% bolus insulin; CSII users: -1h target 150 mg/dL
Active Comparator: MDI users; Patients using Multiple Daily Injections (only Tresiba and Toujeo as basal insulin)	Other: CPET: CardioPulmonary Exercise Test for MDI users; Baseline; VO2peak measurement; Breakfast; 100% bolus insulin; MDI users: 100% basal; Other: AEX1: Aerobic Exercise Test 1 for MDI users; 90min; 40-45% VO2peak; Breakfast; 50% bolus insulin; MDI users: 50% basal; Other: AEX2: Aerobic Exercise Test 2 for MDI users; 90min; 40-45% VO2peak; Breakfast; 50% bolus insulin; MDI users: 80% basal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CGM outcomes during and after morning exercise	CGM outcomes, determined as: Time in range (TIR) 70-180mg/dL; Time below range (TBR) Level 2, <54 mg/dL; Time below range (TBR) Level 1 and 2, <70 mg/dL; Time above range (TAR) Level 1 and 2, >180 mg/dL; Time above range (TAR) Level 2, >250 mg/dL	CGM values will be collected up to 8 hours prior to the exercise test and 24 hours after the exercise test

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in glucose concentration in venous blood during and after morning exercise test	Glucose levels in mg/dL during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET & AEX1-2), measured through EKF	Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in lactate concentration in venous blood during and after morning exercise test	Lactate levels in mM during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET & AEX1-2), measured through EKF	Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in ketone concentration in venous blood during and after morning exercise test	Ketone (Beta-hydroxybutyrate) levels in mM during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET & AEX1-2), measured through EKF	Blood sampling was done before the exercise, every 3-10 minutes during the exercise and every 15 minutes during the first hour of recovery and every 30-60 minutes during the rest of the 6-hour follow-up
Change in cortisol concentration in venous blood during and after morning exercise test	Cortisol levels during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET & AEX1-2), measured through venous blood sampling analysis	Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up
Change in growth hormone concentration in venous blood during and after morning exercise test	Growth hormone levels during and after CardioPulmonary Exercise Test and 2 morning Aerobic Exercise Tests (90 minutes at 40-45% of VO2 max) (CPET & AEX1-2), measured through venous blood sampling analysis	Blood sampling was done before the exercise, every 15-30 minutes during the exercise and every 15-30 minutes during the first hour of recovery and every 60-120 minutes during the rest of the 6-hour follow-up

Collaborators and Investigators

• Sponsor: University Hospital, Antwerp
• Collaborators: Universiteit Antwerpen; York University
• Investigators: Principal Investigator: Christophe De Block, MD, PhD, University Hospital, Antwerp

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2022
• Primary Completion (Anticipated): August 31, 2023
• Study Completion (Anticipated): March 31, 2024

Study Registration Dates

• First Submitted: June 17, 2022
• First Submitted That Met QC Criteria: June 17, 2022
• First Posted (Actual): June 23, 2022

Study Record Updates

• Last Update Posted (Actual): September 6, 2022
• Last Update Submitted That Met QC Criteria: August 31, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Keywords: exercise; biomarker; continuous glucose monitoring; glucose; lactate; ketones; hormones
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: ACT-ONE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No